https://www.selleckchem.com/products/as601245.html
Tigecycline, a new agent against multidrug-resistant (MDR) bacteria, is especially licensed for use in complicated skin and soft tissue and intra-abdominal infections. We aimed to study the recent activity of tigecycline against MDR skin and soft tissue isolates. Consecutive isolates (56 , 48 ) were subjected to tigecycline susceptibility testing by Ezy MIC test and interpreted as per European Committee on Antimicrobial Susceptibility Testing. The minimum inhibitory concentrations (MICs) of tigecycline ranged from 0.016 to 48μg/mL, wit
Like
Comment
Share
